BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...
Eli Lilly and Nvidia are launching a joint artificial intelligence lab in South San Francisco with 70 people to speed up drug ...
6hon MSN
Beyond the brand names: Everything you need to know about Ozempic and other GPL-1 medications
Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the ...
Eli Lilly is already one of the most innovative companies in the pharmaceutical industry. Over the past five years, it has ...
Public Citizen filed a lawsuit against the Trump administration in the U.S. District Court for the District of Columbia ...
Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene ...
SHANGHAI, Jan 30 () - Sciwind Biosciences' type 2 diabetes treatment Xianyida was approved for use in China, the company ...
6don MSN
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...
By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...
Patients know about nausea and vomiting. Now, lawsuits are raising concerns about vision loss.
While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP ...
News Nation on MSN
Patients sue GLP-1 drugmakers, alleging severe side effects
Some patients have pointed to severe undisclosed side effects, including blindness, loss of brain function and organ damage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results